VPC-70619
VPC-70619 is a potent N-Myc inhibitor. VPC-70619 blocks the binding of the N-Myc-Max heterocomplex to the DNA E-box and exhibits potent inhibitory activity against N-Myc-dependent cell lines. VPC-70619 can partially reverse paclitaxel resistance in cells by reducing MYCN expression. VPC-70619 can be used for cancer research (e.g., neuroblastoma and thyroid cancer)[2].
Product Specifications
CAS Number
2361742-30-3
UNSPSC
12352005
Target
C-Myc
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vpc-70619.html
Purity
99.93
Solubility
DMSO : ≥ 100 mg/mL
Smiles
N#CC1=CC(C(F)(F)F)=C(C=C1)NNC(C2=CC=C(C(Cl)=C2)C#N)=O
Molecular Formula
C16H8ClF3N4O
Molecular Weight
364.71
References & Citations
[1]Ton AT, et al. Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer. Int J Mol Sci. 2022;23 (5) :2588. Published 2022 Feb 26. |[2]Molteni E, et al. GSK2801 Reverses Paclitaxel Resistance in Anaplastic Thyroid Cancer Cell Lines through MYCN Downregulation. Int J Mol Sci. 2023 Mar 22;24 (6) :5993.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
PKSM040329 100 µg
Recombinant Mouse Siglec-2/CD22 Protein (His Tag)
Sign In for Pricing
View Details 
